Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results
January 09, 2023 09:00 ET
|
Telesis Bio
-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer...
Telesis Bio Inc. Reports Third Quarter 2022 Financial Results
November 08, 2022 16:10 ET
|
Telesis Bio
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to...
Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8
November 02, 2022 16:19 ET
|
Telesis Bio
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022...
Telesis Bio und Cellibre kündigen Zusammenarbeit an, um die Entwicklung des künftigen BioXp® DBC-Instruments zu optimieren
October 19, 2022 17:33 ET
|
Telesis Bio
SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), ein führendes Unternehmen für automatisierte Multi-Omics- und synthetische Biologielösungen, und Cellibre, ein führendes...
Telesis Bio et Cellibre annoncent une collaboration pour optimiser le développement du futur instrument BioXp® DBC
October 19, 2022 17:33 ET
|
Telesis Bio
SAN DIEGO, 19 oct. 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq : DNAY), leader des solutions de biologie synthétique et multi-omique automatisées, et Cellibre, une société de premier plan...
Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument
October 19, 2022 09:00 ET
|
Telesis Bio
SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company,...
Codex DNA kündigt Plan zur Umfirmierung in Telesis Bio an
October 12, 2022 13:04 ET
|
Codex DNA, Inc.
SAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), ein führendes Unternehmen für automatisierte Multi-Omics- und synthetische Biologielösungen, gab heute seinen Plan zur...
Codex DNA annonce son intention de changer son nom d'entreprise en Telesis Bio
October 12, 2022 13:04 ET
|
Codex DNA, Inc.
SAN DIEGO, 12 oct. 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq : DNAY), un leader des solutions de biologie multiomique et synthétique automatisées, a annoncé aujourd'hui son intention de...
Codex DNA Announces Plan to Change Corporate Name to Telesis Bio
October 12, 2022 09:00 ET
|
Codex DNA, Inc.
SAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced a plan to change its Company name to...
Codex DNA étend l'application de la technologie exclusive de correction des erreurs
October 04, 2022 09:00 ET
|
Codex DNA, Inc.
SAN DIEGO, 04 oct. 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ : DNAY), un pionnier des systèmes de paillasse automatisés de biologie synthétique, a annoncé aujourd'hui le lancement commercial...